神奇制药-神奇B股被警示，股民索赔可期

Core Viewpoint - Shanghai Magical Pharmaceutical Co., Ltd. has been found to have violated information disclosure regulations, leading to administrative regulatory measures from the China Securities Regulatory Commission (CSRC) [1] Summary by Sections Company Violations - In 2023, the company misappropriated sales expenses amounting to 44,838,280 yuan through a halted "basic drug promotion plan" and created fictitious accounts receivable, which had already been fully impaired [1] - This led to incorrect information being disclosed in the company's 2023 annual report, violating Article 3, Paragraph 1 of the "Administrative Measures for Information Disclosure by Listed Companies" [1] Regulatory Actions - The CSRC's Shanghai Bureau has mandated corrective actions for the company and issued warning letters to individuals including Zhang Tao Tao, Feng Bin, and Chen Zhimian [1] Legal Implications for Investors - Investors who suffered losses due to the company's violations can seek civil compensation, which includes investment differences, commissions, and stamp duties [2] - A lawyer is actively recruiting affected investors for litigation against the company, specifically targeting those who purchased shares between April 29, 2024, and September 26, 2025 [2] Litigation Process - While investors can file lawsuits without prior administrative penalties, the lack of thorough investigation may increase the risk of losing the case [3] - The status of the company, including potential delisting or bankruptcy, may affect the litigation process but does not halt it [3] Required Documentation for Claims - Investors must provide specific documents for compensation claims, including a copy of their ID, securities account information, and transaction records [3]